Tumorad® (¹⁷⁷Lu-SN201)
Advanced Solid Tumors (e.g., Ovarian Cancer, Triple-Negative Breast Cancer)
Phase I/IIaActive - Recruiting
Key Facts
Indication
Advanced Solid Tumors (e.g., Ovarian Cancer, Triple-Negative Breast Cancer)
Phase
Phase I/IIa
Status
Active - Recruiting
Company
About Spago Nanomedical
Spago Nanomedical is a clinical-stage company developing targeted cancer therapies and diagnostics via its patented polymeric nanoparticle platform. Key achievements include a positive DMC recommendation and proof-of-concept in its Phase I/IIa Tumorad-01 study, and clinical validation of its SpagoPix MRI agent. The company's strategy is to advance its pipeline to key inflection points before pursuing out-licensing deals with larger partners for global commercialization.
View full company profile